Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with T cell acute lymphoblastic leukemia (T cell ALL) and whose cancer has gone into remission (complete or partial) after at least 2 rounds of intensive chemotherapy.
• People whose cancer is in remission but where sensitive testing still detects a small number of cancer cells at a level of 1 in 10,000 or more (called MRD-positive), confirmed by a central laboratory using a test called flow cytometry.
• People who have previously had a stem cell transplant from a donor, as long as they do not have a complication called graft-versus-host disease (GVHD) that requires ongoing immune-suppressing medication (low-dose prednisone of 10 mg per day or less may be acceptable — confirm with trial site).
• People who are reasonably well and able to carry out everyday activities, as measured by a standard medical scale (ECOG score of 0, 1, or 2).
• People whose blood test results taken within 7 days before registering show that their bone marrow, liver, and kidneys are functioning at an adequate level, as defined by specific laboratory thresholds.
• People who are HIV-positive and on effective treatment with an undetectable level of virus in the blood within the past 6 months.
• People with a history of chronic hepatitis B, provided the virus is undetectable on appropriate treatment.
• People with a history of hepatitis C who have been successfully treated and cured, or who are currently on treatment with an undetectable viral load.
• People who previously had cancer involvement in the brain or spinal fluid, as long as there is no active involvement at the time of registration.
• People with a history of another cancer, as long as that cancer or its treatment is not expected to interfere with the safety or results of this trial.
• People with a history of heart disease or treatment with heart-affecting medications, provided a doctor's assessment rates their heart function as class 2B or better on a standard heart health scale.
• People who are able to understand and sign a consent form, including those who cannot make decisions for themselves if a legally authorised representative, caregiver, or family member is available to assist.
• People of childbearing potential who have had a pregnancy test (blood or urine) within 14 days before registering, confirming they are not pregnant.
• People who agree to use effective contraception or abstain from sex for the entire time they are in the study and for 3 months after the last dose of treatment, and who agree not to donate sperm or eggs during that same period.

Who may not be able to join:

• People who are currently pregnant or breastfeeding, due to potential harm to an unborn baby or nursing infant from the treatments used in this trial.

Important: Always verify eligibility with the trial site directly before applying.